|
Liver carcinoma
|
0.310 |
Biomarker
|
disease |
BEFREE |
Survival analysis of all HCC patients in TCGA indicated that the overall survival and disease-free survival were not significantly associated with <i>VSIG4</i> expression.
|
30288101 |
2018 |
|
Arthritis
|
0.020 |
Biomarker
|
disease |
BEFREE |
A soluble form of CRIg reversed inflammation and bone loss in two experimental models of arthritis by inhibiting the AP of complement in the joint.
|
17548523 |
2007 |
|
Arthritis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Here, we further addressed the specificity and assessed the potential for arthritis monitoring using near-infrared fluorescence (NIRF) Cy7-labeled Vsig4 nanobody (Cy7-Nb119).
|
31288389 |
2019 |
|
Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The Ig superfamily protein PTGFRN coordinates survival signaling in glioblastoma multiforme.
|
31377205 |
2019 |
|
Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Contrary to VSIG4, we demonstrated that overexpressing let-7g-5p promoted mesenchymal-epithelial transition (MET) and significantly inhibited invasion and migration consistent with the reduction of glioblastoma stem cell phenotypes in U-87MG cells.
|
27634309 |
2016 |
|
Glioblastoma Multiforme
|
0.020 |
Biomarker
|
disease |
BEFREE |
The Ig superfamily protein PTGFRN coordinates survival signaling in glioblastoma multiforme.
|
31377205 |
2019 |
|
Glioblastoma Multiforme
|
0.020 |
Biomarker
|
disease |
BEFREE |
Contrary to VSIG4, we demonstrated that overexpressing let-7g-5p promoted mesenchymal-epithelial transition (MET) and significantly inhibited invasion and migration consistent with the reduction of glioblastoma stem cell phenotypes in U-87MG cells.
|
27634309 |
2016 |
|
Rheumatoid Arthritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We examined expression of Z39Ig in 1432 human cDNA libraries, and found it primarily in synovium of patients with rheumatoid arthritis, in placenta, and in lung.
|
11997108 |
2002 |
|
Autoimmune Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Here, we review our current understanding of the diverse roles of CRIg in pathogen elimination, anti-microbial immunity and autoimmunity.
|
29573978 |
2018 |
|
Bacterial Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
Extracellular stimulation of VSIG4/complement receptor Ig suppresses intracellular bacterial infection by inducing autophagy.
|
27440002 |
2016 |
|
Benign Ovarian Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Soluble VSIG4 concentrations were increased in patients with ovarian cancer compared with that in patients with benign ovarian tumors (P = 0.0452).
|
28498255 |
2017 |
|
Malignant Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
High VSIG4 expression of cancer tissue and low VSIG4 expression of plasma (soluble VSIG4) were associated with a longer disease-free interval (P = 0.0246 and 0.0398, respectively).
|
28498255 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, 10 human non-small-cell lung cancer specimens were collected and immunohistochemically analyzed for VSIG4 expression.
|
24862966 |
2014 |
|
Intracranial Aneurysm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Among all DEGs, 5 down-regulated genes (MYH11, CNN1, MYOCD, ACTA1, and LMOD1) and 3 up-regulated genes (C1QB, C3AR1, and VSIG4) are most relevant in IA formation.
|
31238169 |
2019 |
|
Diabetic Nephropathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Correlation analysis between unexplored hub genes and clinical features of DN suggested that COL6A3, MS4A6A,PLCE1, TNNC1, TNNI1, TNN2, and VSIG4 may involve in the progression of DN.
|
30485525 |
2018 |
|
Encephalomyelitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The agonistic VSIG4 antibodies (VG11), acting through NLRP3 and IL-1β suppression, show significant therapeutic efficacy in mouse EAE.
|
30662948 |
2019 |
|
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, we concluded that let-7g-5p inhibits epithelial-mesenchymal transition (EMT) consistent with reduction of glioma stem cell (GSC) phenotypes by targeting VSIG4 in glioblastoma.
|
27634309 |
2016 |
|
Congestive heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
In an unbiased approach, the top 10 DEGs SERPINA3, SERPINA5, LCN6, LCN10, STEAP4, AKR1C1, STAC2, SPARCL1, VSIG4 and F8 exhibited no overlap in read counts between DON and HF RVs, high sensitivities, specificities, predictive values and areas under the receiver operating characteristic curves.
|
25725476 |
2015 |
|
Hepatitis
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Hepatic VSIG4 expression was not associated with liver inflammation (0.00; 95% CI -0.15, 0.15).
|
29902703 |
2018 |
|
Hepatitis B
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our study suggests that VSIG4 is downregulated in HCC, and low expression of VSIG4 is associated with poor prognosis in hepatitis B virus-related HCC patients.
|
30288101 |
2018 |
|
Multiple Myeloma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We assessed the VSIG4 expression in patients with MM and its prognostic impact.
|
28938542 |
2017 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Bioinformatics analysis showed that <i>VSIG4</i> expression was downregulated in HCC tissues, and the expression level of <i>VSIG4</i> was negatively correlated with serum alpha fetal protein (AFP) level and tumor distant metastasis.
|
30288101 |
2018 |
|
Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Bioinformatics analysis showed that <i>VSIG4</i> expression was downregulated in HCC tissues, and the expression level of <i>VSIG4</i> was negatively correlated with serum alpha fetal protein (AFP) level and tumor distant metastasis.
|
30288101 |
2018 |
|
Obesity
|
0.010 |
Biomarker
|
disease |
BEFREE |
Vsig4 <sup>-/-</sup> mice are susceptible to high-fat diet-caused obesity and murine hepatitis virus strain-3 (MHV-3)-induced fulminant hepatitis due to excessive macrophage-dependent inflammation.
|
29109438 |
2017 |
|
Osteopenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
A soluble form of CRIg reversed inflammation and bone loss in two experimental models of arthritis by inhibiting the AP of complement in the joint.
|
17548523 |
2007 |